Acumen Pharmaceuticals Stops Sabirnetug After Phase 2 Miss, Shares Crash
The company will cease development of the drug and conserve cash after missing clinical endpoints.
Already have an account? Sign in.
The company will cease development of the drug and conserve cash after missing clinical endpoints.
Be the first to know when deals break, stocks move, or biotech headlines hit.